Innoviva, a firm that develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms, completed the acquisition of the remaining stake in Entasis Therapeutics, a late-stage clinical biopharmaceutical company, for $45m. "This acquisition will build upon our overall strategy to acquire differentiated, high-potential assets in attractive, yet often overlooked, disease areas where our capital and capabilities can make a difference. This transaction represents the next phase in our efforts to diversify our operations beyond our valuable royalty portfolio and will create significant value for patients, health systems and shareholders. We look forward to working with the Entasis team to advance sulbactam-durlobactam and its broader novel antibacterial pipeline to address the urgent and serious threat posed by multidrug-resistant pathogens," Pavel Raifeld, Innoviva CEO.